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Purpose: Evaluate the safety and efﬁcacy of cryopreserved amniotic cytokine extract (ACE)
in the treatment of subjects with dry eye disease (DED).
Patients and methods: This was a retrospective, multicenter, chart review of adult
patients with DED that instilled cryopreserved ACE drops twice-daily for 4 or 12 weeks.
Patients had corneal ﬂuorescein staining (0–20 range) and/or a lissamine green conjunctival
staining score (0–18 range) of ≥3 and ≤9 in at least 1 eye and a score ≥40 (0–100 range) of
eye dryness/irritation on a visual analog scale (VAS). Following completion of a treatment
course, medical records were reviewed from the initiation of therapy (baseline), and at posttreatment visits (4 weeks, 8 weeks, and 12 weeks). Patient records for visual acuity, adverse
events, corneal ﬂuorescein staining, conjunctival lissamine green staining, and symptom
scores of ocular dryness/irritation were reviewed for each visit, as available. Safety and
tolerability were assessed through the evaluation of patient-reported adverse events recorded
in the medical records.
Results: A total of 54 eligible patients were identiﬁed at 7 clinical sites; 16 patients
administered ACE drops for 4-weeks, and 38 patients instilled ACE drops for 12 weeks.
Signiﬁcant improvements in the mean changes from baseline were observed for corneal
ﬂuorescein staining, lissamine green staining, visual acuity (LogMar) and VAS ocular
symptom scores at the 4-week post-treatment visit (p<0.01). Additional improvements
continued out to the 12-week follow-up assessment visits. Two patients discontinued therapy
due to reports of ocular burning or foreign body sensation.
Conclusion: The cryopreserved ACE formulation was well-tolerated and effective in reducing the clinical signs and symptoms of DED. Conduct of a vehicle-controlled prospective
study is warranted.
Keywords: dry eye, amniotic membrane, amnion extract, cytokine, inﬂammation

Introduction

Correspondence: Damien F Goldberg
Wolstan & Goldberg Eye Associates,
23600 Telo Ave., #100, Torrance, CA
90505, USA
Tel +1 310 543 2611
Fax +1 310 543 2056
Email goldbed@hotmail.com
submit your manuscript | www.dovepress.com

DovePress
http://doi.org/10.2147/OPTH.S203510

Dry eye disease (DED) is a common condition with multifactorial etiologies
characterized by tear ﬁlm instability and ocular surface inﬂammation.1 The clinical
presentation of DED includes disruptions in the integrity of the corneal and conjunctival epithelium, a rapid tear break-up time, and reports of a range of symptoms
associated with ocular discomfort and irritation, including dryness, grittiness, and
foreign body sensation.1,2 Multiple subtypes of DED may occur within patients,
including aqueous-deﬁcient and evaporative forms of the disease, with overlap
being common, as well as comorbidity with other ocular conditions, such as
blepharitis.2,3 The prevalence of DED varies across studies due to differences in
study population and diagnostic criteria, with estimates ranging from 5% to 50% of
Clinical Ophthalmology 2019:13 887–894
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the study population based on the presence of symptoms
with or without clinical signs.4 Risk factors that are commonly associated with DED include advancing age, female
gender, meibomian gland dysfunction, a history of ocular
surgery, contact lens wear, and exposure to low humidity
or high airﬂow.4
A range of non-pharmacological and pharmacological
therapies have been evaluated and recommended for the
treatment of patients with DED through the use of stagedtreatment algorithms based on the nature and severity of the
patient’s condition. Inﬂammation of the ocular surface is
a common factor across patients and is often a target for
therapy, with treatment options including topical antiinﬂammatory and/or immunomodulatory agents. One form
of therapy that has been recommended for the treatment of
DED includes amniotic membrane transplantation.3,5
In cases of severe conditions affecting the ocular surface that can result in alteration of the function and integrity of the tear ﬁlm, including conjunctival scarring,
trauma, and persistent epithelial defects, transplantation
of amniotic membrane is recognized as a therapeutic treatment option. Amniotic membrane, the thin avascular inner
layer of the fetal membranes, may be transferred to the
ocular surface as a temporary graft to act as a bandage,
shielding ocular tissue, as well as promoting healing of the
damaged structures. The transparent amniotic membrane
has been demonstrated to promote epithelialization, and
possess anti-inﬂammatory, anti-angiogenic, and antiﬁbrotic properties.3,6 Preserved amniotic membrane has
been used to treat patients with DED, resulting in improvements in patient-reported ocular symptoms and clinical
signs, as well as corneal nerve restoration.7–9
The improvements in ocular surface healing and comfort
associated with amniotic membrane transplantation have
been attributed in part to the anti-inﬂammatory properties
of the tissue, inhibiting the expression of pro-inﬂammatory
mediators and growth factors. Interest in the potential for
improvements in wound healing and other applications of the
properties of amniotic tissue has led to the development of
extracts. Amnion-derived extract solutions have been
demonstrated to contain combinations of cytokines, growth
factors, and inhibitors of enzymes involved in tissue remodeling (matrix metalloproteinases).10,11
A cryopreserved eyedrop formulation of amniotic cytokine extract (ACE) was developed and launched in 2017
(Genesis, Ocular Science, Manhattan Beach, CA). The
ACE formulation was prepared through a proprietary cryopreservation method using a compounding pharmacy and
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contains soluble mediators that have been shown to stimulate healing and reduce inﬂammation. This report presents
the results of a retrospective analysis of the safety and
efﬁcacy of ACE drops for the treatment of patients
with DED.

Patients and methods
This was a retrospective chart review designed to evaluate
the safety and efﬁcacy of the use of ACE in the treatment of
patients with DED. The study was approved by the Duke
University (Durham, NC, USA) Institutional Review Board
(IRB) and Sterling IRB (Atlanta, GA, USA) as a central
review board for the other clinical sites. A waiver was
obtained for collection of informed consent and the authorization to use of protected health information. The study
was performed in accordance with the Declaration of
Helsinki and the Health Insurance Portability and
Accountability Act. Patient medical records were evaluated
at 7 clinical centers in the United States.

Study design and participants
The medical records of patients with symptomatic DED that
were treated with ACE were reviewed. The study dates
ranged from patients that initiated treatment on January 12,
2017, through March 21, 2018. Patient groups included
2 arms of treatment: topical bilateral administration of ACE
drops twice daily for a 4-week treatment period, and patients
that administered ACE drops twice daily for a 12-week
treatment period. Retrospective data from medical charts
were collected at the following times: prior to the initiation
of ACE topical therapy (baseline), 4 weeks (±2 days), 8
weeks (±2 days), and 12 weeks (±2 days) after beginning
ACE treatment.
The inclusion criteria for the study allowed for evaluation of patient medical records that were 18 years of age or
older with a diagnosis of mild, moderate, or severe DED.
In addition to a patient-reported history of DED for
a period of at least 6 months, a clinical diagnosis of
bilateral DED was required at the baseline assessment.
Eligible participants had to have a total corneal ﬂuorescein
staining score of ≥3 and ≤9 out of a possible score of 0–20
in at least 1 eye or a conjunctival lissamine green staining
score of ≥3 and ≤9 out of a possible score of 0–18 in at
least 1 eye at baseline. Patients were also required to have
a baseline symptom score of ≥40 for eye irritation/dryness
on a visual analog scale (VAS) on a 0–100 scale. Only
patients with a Snellen visual acuity of 20/200 or better
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were included in the study population. All patients that
met inclusion criteria from the study sites were included.
Patients were excluded from the study if any of the
following criteria were met: current diagnosis or history of
seasonal or perennial allergic conjunctivitis, unstable macular disease, diagnosis of herpes keratitis, presence of
chronic uveitis, prior history of corneal transplant refractive
surgery, cataract surgery, glaucoma treatment surgical procedures (or laser treatment) within 3 months of the baseline
evaluation, recent punctal plug placement (within 3
months), lagophthalmos or other clinically signiﬁcant eyelid margin irregularity, clinically signiﬁcant conjunctivochalasis, presence of pterygium, use of contact lenses,
current or recent use (within 30 days of the baseline assessment) of liﬁtegrast ophthalmic solution 5% (Xiidra; Shire,
Lexington, MA) or cyclosporine ophthalmic emulsion
0.05% (Restasis; Allergan, Irvine, CA), patients that were
human immunodeﬁciency virus positive, women who were
pregnant or breastfeeding, patients that had a current active
ocular disease other than DED, or other serious or unstable
medical condition. Patients that were on immunomodulator
medications and omega-3 fatty acid supplements were
included in the chart review if the dose was stable for 3
months prior to the baseline evaluation, and the dose did not
change during the ACE treatment period. Patient data were
not included if any other ophthalmic medications were used
during the ACE treatment period.

Study assessments
Demographic information (gender) was collected at the
baseline visit. Data were collected as part of the retrospective chart review for the following parameters (if recorded):
visual acuity, symptom score assessed as the severity and
frequency of eye dryness/irritation over the past week on
a VAS scale (0–100 range with 0= no dryness/irritation and
100= severe dryness/irritation), total corneal ﬂuorescein
staining score (0–4 severity scale; 0= no punctate staining,
4= severe diffuse/coalescent macropunctate staining) for
each region of the cornea (central, inferior, superior, medial,
lateral) with a total possible score of 0–20, conjunctival
lissamine green staining on a 0–3 scale (0= no punctate
staining, 3= densely concentrated micropunctate staining;
NEI scale) for each of 6 regions of the conjunctiva
(temporal, nasal, 2 inferior regions, and 2 superior regions)
with a total possible score of 0–18.12 Safety and tolerability
of the ACE formulation was assessed through the evaluation of patient-reported adverse events recorded in the
patients’ medical records.
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Statistical methods
Descriptive statistics were calculated (mean values, standard deviation [SD] and 95% conﬁdence limits) for chart
review assessment parameters, including visual acuity
(LogMAR), eye dryness/irritation VAS score, total corneal
ﬂuorescein staining score, and total conjunctival lissamine
green staining score. Statistical analysis was performed to
compare the visual acuity, VAS scores, and staining scores
at the 4-week, 8-week, and 12-week post-treatment assessments to the baseline parameters. The analysis presented
for the 4-week post baseline assessments combines data
from both treatment arms (both the 4-week and 12-week
treatment groups were on the same treatment regimen
through week 4). The study eye for each patient was
deﬁned based on the eye that had the highest total corneal
ﬂuorescein staining score at the baseline assessment. The
results of the analysis are presented for the study eye for
all recorded parameters except for the eye dryness/irritation assessment where only one score was recorded for
each patient.
Patient records without baseline or any post baseline
assessments were excluded from the analysis. A paired
t-test was used to analyze within-group changes from
baseline. No adjustment was made to p-values due to
multiple comparisons. Data analysis was conducted using
Statistical Analysis System (SAS®) Software version 9.4
(SAS Institute, Cary, NC).

Results
A total of 54 patients met the eligibility criteria and
were included in the study analysis; 16 patients were
identiﬁed that had administered ACE drops for 4 weeks,
and 38 patients were identiﬁed for the 12-week treatment period. The data that was identiﬁed from the
medical records for eligible patients is presented for
each endpoint; not all patients that were determined to
be eligible for inclusion in the study analysis returned
to the clinic for all the assessment visits. The majority
of eligible patients were female for each group (10 out
of 16 [62.5%] patients in the 4-week treatment group,
and 29 out of 38 [76.3%] patients in the 12-week
group) and overall (39 out of 54 total patients;
72.2%). The baseline characteristics of the patients by
treatment group and for the overall study population,
including mean (SD) scores for eye dryness/irritation,
total corneal staining, total conjunctival staining, and
visual acuity, are listed in Table 1. The baseline
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Table 1 Baseline characteristics of the study population
Parameter

ACE
Group 1
4-Week

ACE
Group 2
12-Week

Overall

Eye Dryness/Irritation;
VAS (01–100)
N

15

38

53

Mean (SD)

72.3 (14.7)

68.3 (19.8)

69.5 (18.4)

95% CI

(64.2, 80.5)

(61.8, 74.8)

(64.4, 74.5)

Total Corneal Staining
(01–100)
N

16

38

54

Mean (SD)
95% CI

4.3 (3.6)
(2.3, 6.2)

9.4 (4.6)
(7.9,10.9)

7.9 (4.9)
(6.5, 9.2)

Total Conjunctival
Staining (0–18)
N

16

38

54

Mean (SD)
95% CI

9.1 (6.4)
(5.7, 12.5)

5.9 (3.5)
(61.8, 74.8)

6.8 (4.7)
(0.4, 74.5)

Visual Acuity (LogMAR)
N

10

38

48

Mean (SD)

0.12 (0.11)

0.26 (0.22)

0.23 (0.21)

95% CI

(0.04, 0.19)

(0.19, 0.34)

(0.17, 0.29)

Notes: Group 1 included patients that administered ACE drops twice daily for a 4week treatment period, and Group 2 included patients that administered ACE
drops twice daily for a 12-week treatment period.
Abbreviations: ACE, amniotic cytokine extract; CI, conﬁdence interval; LogMar,
logarithm of the Minimum Angle of Resolution; SD, standard deviation; VAS, visual
analog scale.

characteristics were generally similar between the overall study population and the 4-week and 12-week ACE
treatment groups.

Efﬁcacy assessments
Eye dryness/irritation
The mean (SD) change from baseline in VAS scores for eye
dryness/irritation is presented by assessment time point in
Figure 1. Signiﬁcant improvements in patient-reported
symptoms were observed at each post-baseline visit, including the 4-week evaluation, and continued to improve out to
the 12 assessments (p<0.01). Analysis of the distribution of
patient responses indicated that 81% of the subjects reported
an improvement of at least 30% and 67% of the subjects
reported an improvement of at least 40% at week 12.

Ocular surface staining
Mean (SD) change from baseline in total corneal ﬂuorescein staining scores are presented at baseline and for each
follow-up visit in Figure 2. Signiﬁcant improvements in
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corneal staining were observed beginning at the 4-week
assessment and improvements continued to the 12-week
assessment (p<0.01). Examination of the distribution in
total corneal staining scores indicated that an improvement
of at least 50% was observed in 95% of the patients at
week 12. Similar corresponding improvements in the mean
(SD) total conjunctival lissamine green staining were
observed; the mean change from baseline in conjunctival
lissamine green staining is presented by follow-up visit in
Figure 3. Signiﬁcant improvements in the mean change
from baseline in total conjunctival staining were observed
at week 4, week 8, and week 12 assessments (p<0.01).

Safety assessments
Visual acuity assessments generally remained stable or
showed modest improvement throughout the treatment
and follow-up period. The mean (SD) change from baseline in visual acuity scores (LogMAR) are presented by
visit in Figure 4. Based on the review of patient medical
records, 2 patients complained of ocular burning after
instillation, with 1 patient discontinuing therapy, and 1
patient discontinued therapy due to a report of foreign
body sensation. No other adverse events were reported
during the ACE treatment or follow-up period.

Discussion
The ACE formulation used by patients in this study population is a cryopreserved solution containing over 120 cytokines, growth factors, and anti-inﬂammatory agents. The
ACE solution is prepared using a proprietary cryopreservation technique to harvest a combination of biologically active
molecules that contribute to wound healing and a reduction
of inﬂammation. Key factors that have been identiﬁed in the
extracts of amniotic tissue include prostaglandin E2
(PGE2),13 growth differentiation factor 11 (GDF11),14,15
thrombospondin-1,16 and WNT4.17 PGE2 has been identiﬁed
as a major mediator found in mesenchymal stem cell extracts
capable of modulating the immune response through the
induction of differentiation of naïve T cells into regulatory
T cells and the promotion of IL-10 production.13
The etiology of DED is complex with multiple pathways for initiation of the chronic inﬂammatory response
that is characteristic of the condition.18 A chronic cycle of
inﬂammation that occurs in patients with DED can be
related to other ocular conditions or associated with
damage that occurs to the ocular surface through tear
ﬁlm hyperosmolarity. The release of proinﬂammatory
mediators, including cytokines and increase in expression
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Mean change from baseline in eye
dryness/irritation VAS (SD)

0

-10

-20

-30

-40

-50
p<0.01
-60
p<0.01

p<0.001

-70
Baseline
(n = 53)

Week 4
(n = 50)

Week 8
(n = 31)

Week 12
(n = 21)

Figure 1 The mean changes from baseline in the subject-reported symptoms of ocular dryness/irritation assessed by visual analog scale (VAS) on a 0–100 scale (0= no
ocular dryness/irritation, 100= severe ocular dryness/irritation) are presented by visit. The mean changes from baseline were considered statistically signiﬁcant at week 4 and
week 8 (p<0.01), and week 12 (p<0.001). A paired t-test was used to analyze within-group changes from baseline.Abbreviations: SD, standard deviation; VAS, visual analog
scale.

Mean change from baseline in total
corneal staining score (SD)

-1
-2
-3
-4
-5
-6
-7
-8

p<0.01

-9

p<0.01

-10
Baseline
(n = 53)

Week 4
(n = 50)

Week 8
(n = 30)

p<0.001
Week 12
(n = 21)

Figure 2 The mean changes from baseline in the corneal ﬂuorescein staining on a 0–20 scale (0–4 scale per region for each of the 5 regions of the cornea) are presented by
visit. Analysis of the mean changes from baseline in corneal ﬂuorescein staining indicated that the improvements were statistically signiﬁcant at week 4 (p<0.01), week 8
(p<0.01), and week 12 (p<0.001). A paired t-test was used to analyze within-group changes from baseline.Abbreviation: SD, standard deviation.

of matrix metalloproteinase enzymes can enhance recruitment of immune cells to the ocular surface, further disrupting the tear ﬁlm.19 Methods of treatment for DED

Clinical Ophthalmology 2019:13

designed to address inﬂammation include agents with
a speciﬁc target as the method of action, such as calcineurin inhibitors (cyclosporine) and lymphocyte-function-
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4

Mean change from baseline in total
conjunctival staining score (SD)

2

0

-2

-4

-6
p<0.01

p<0.01

-8
Baseline
(n = 53)

Week 4
(n = 50)

Week 8
(n = 31)

p<0.001
Week 12
(n = 21)

Figure 3 The mean changes from baseline in the conjunctival lissamine green staining on a 0–18 scale (0–3 scale per region for each of the 6 regions of the conjunctiva) are
presented by visit. Changes from baseline were determined to be statistically signiﬁcant at week 4 (p<0.01), week 8 (p<0.01), and week 12 (p<0.001). A paired t-test was
used to analyze within-group changes from baseline.Abbreviation: SD, standard deviation.

Mean change from baseline in visual
acuity-logMAR (SD)

0.21

0.05

0

-0.05

-0.1

-0.15
p<0.01
-0.2

p<0.01
p<0.001

-0.25

Baseline
(n = 53)

Week 4
(n = 50)

Week 8
(n = 31)

Week 12
(n = 21)

Figure 4 The mean changes from baseline in visual acuity (LogMAR) are presented by visit. SD = standard deviation. The improvement from baseline at follow-up visits was
statistically signiﬁcant at week 4 (p<0.01), week 8 (p<0.01), and week 12 (p<0.001). A paired t-test was used to analyze within-group changes from baseline.Abbreviation:
SD, standard deviation.

associated antigen-1 (LFA-1) antagonists (liﬁtegrast), as
well as topically applied corticosteroids which function
as general anti-inﬂammatory agents.5,20
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Although the precise mechanism of action of the ACE
formulation in the treatment of patients with DED is
unknown, a combined effect is likely due to the diverse
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complement of biologically active agents that have been
identiﬁed as present in amniotic tissue extracts at physiological concentrations.11 Amniotic membrane extract preparations contain many of the similar properties to
cryopreserved amniotic membrane. Amniotic tissue
extracts have been evaluated for treatment related to corneal injury and wound healing.21 Pre-clinical evaluation
has also been conducted in a murine model of DED.22 The
results observed in this retrospective analysis on the use of
ACE in the treatment of DED suggest that the beneﬁts of
amniotic membrane treatment for DED may be extended
to the topical formulation of the extract.
Based on the minimal adverse events in the medical
records evaluated in this retrospective study and the
improvements observed in patient-reported symptoms,
the ACE formulation appears to be well tolerated by
patients with DED. Improvements in the clinical signs
and symptoms of DED were observed by the majority of
patients within 4 weeks of initiation of therapy, with
improvements continuing throughout the 12-week followup period.
Limitations of the present study include the small size
of the study population, the retrospective aspect of the
study design, lack of the ability to monitor patient compliance with therapy, and the lack of a comparator control
group. Additionally, the retrospective nature of the study
did not control for the duration of treatment for all patients
evaluated in the study; the duration of treatment for
patients was based on the recommendations for each clinician. Conduct of a controlled, double-masked, prospective
study would help to further elucidate the safety and efﬁcacy proﬁle of the ACE formulation. The ongoing
improvement in signs and symptoms in both the 4-week
and 12-week treatment groups of the current study suggests that evaluation beyond 3 months of treatment and
follow-up may be necessary to determine the optimal
treatment regimen.
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